Trevi Therapeutics (TRVI) Preferred Dividend Payments (2018 - 2019)
Trevi Therapeutics' quarterly Preferred Dividend Payments came in at $3.8 million in Q4 2019, down 33.51% year-on-year from $5.7 million in Q4 2018, and up 200.0% quarter-over-quarter from -$3.8 million in Q3 2019.
Trevi Therapeutics has reported Preferred Dividend Payments for 2 years, with the latest figure at $3.8 million in Q4 2019.
- For the quarter ending Q4 2019, Preferred Dividend Payments fell 33.51% year-over-year to $3.8 million; the trailing twelve-month figure through Dec 2019 stood at -$1.5 million (down 128.42% YoY), and the FY2019 full-year result was $2.2 million, down 58.55% from the prior year.
- Preferred Dividend Payments for Q4 2019 stood at $3.8 million, up from -$3.8 million in the prior quarter.
- The five-year high for Preferred Dividend Payments was $5.7 million in Q4 2018, with the low at -$3.8 million in Q3 2019.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Pref Dividends (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Trevi Therapeutics | 2.02 Bn | 1.85 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2019 | 3.77 Mn |
| Sep 30, 2019 | -3.77 Mn |
| Jun 30, 2019 | -1.33 Mn |
| Mar 31, 2019 | -203,000.00 |
| Dec 31, 2018 | 5.68 Mn |
| Sep 30, 2018 | 96,000.00 |
| Jun 30, 2018 | -175,000.00 |
| Mar 31, 2018 | -195,000.00 |